SEC Company Response from Silexion Therapeutics Corp (SLXN, SLXNW) (CIK 0002022416) (SLXN) — Jun 16, 2026
Silexion Therapeutics Corp (SLXN, SLXNW) (CIK 0002022416)
Date: June 16, 2026 · CIK: 0002022416 · Accession: 0001178913-26-003203
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296739
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Attention: Jason Drory Re: Silexion Therapeutics Corp Registration Statement on Form S-3 Filed June 12, 2026 SEC File Number 333-296739
Dear Mr. Drory:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective at 9:00 a.m., Eastern Time on Thursday, June 18, 2026, or as soon as practicable thereafter.
Please contact Gary Emmanuel, Esq., Greenberg Traurig, LLP, our U.S. legal counsel, at (212) 801-9337 or Gary.Emmanuel@gtlaw.com , or Jonathan M. Nathan, Adv., Meitar Law Offices, our outside (Israeli) legal counsel, at +972-52-312-5574 or jonathann@meitar.com , with any questions, and please notify either of them when this request for acceleration has been granted.
Sincerely,
/s/ Ilan Hadar
Show Raw Text
CORRESP 1 filename1.htm Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606 Telephone: +972-3-756-4999 June 16, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jason Drory Re: Silexion Therapeutics Corp Registration Statement on Form S-3 Filed June 12, 2026 SEC File Number 333-296739 Dear Mr. Drory: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective at 9:00 a.m., Eastern Time on Thursday, June 18, 2026, or as soon as practicable thereafter. Please contact Gary Emmanuel, Esq., Greenberg Traurig, LLP, our U.S. legal counsel, at (212) 801-9337 or Gary.Emmanuel@gtlaw.com , or Jonathan M. Nathan, Adv., Meitar Law Offices, our outside (Israeli) legal counsel, at +972-52-312-5574 or jonathann@meitar.com , with any questions, and please notify either of them when this request for acceleration has been granted. Sincerely, /s/ Ilan Hadar Ilan Hadar Chief Executive Officer CC: Mirit Horenshtein Hadar Silexion Therapeutics Corp Gary Emmanuel, Esq. Greenberg Traurig, LLP Jonathan M. Nathan, Adv. Meitar Law Offices